About two million cancer patients – including 9/11 first response – can finally be cured with a new CAR T drugs, new research suggests.
Later stages of solid tumors, how many breast, lung and mesothelioma patients develop almost impossible to treat and many patients die despite treatment.
In the early stages of clinical trials presented at the American Association for Cancer Research, the first of its kind-tumor immunotherapy cancer cut and shrunk in the blood up to 50 percent of patients with mesothelioma.
It is noteworthy that the researchers Memorial Sloan Kettering sight improvement in their different treatment resistant patients after a single treatment.
New immunotherapy & # 39 is the first in the world to effectively overload the immune cells attack metastisized breast, lung and mesothelioma cancer in the early stage of the proceedings
The researchers found, and to address some of the shortcomings in the immunotherapy of solid tumors in the same breath.
"This approach [a] the first in the world, "lead study author and Sloan Kettering Deputy Chief of Thoracic Surgery, Dr. Prasad Adusumilli Daily Mail Online said in an e-mail.
Cancer is often described as the "fight", and that's just what the doctor Adusumilli and his team approached their study.
He said they first got a better idea of the "battlefield" or tumor environment, and then developed CAR T therapy, which acts as a "precision tool / weapon, without collateral damage," and found that the treatment made a strong "landing" on it the battlefield.
As a result of the treatment, which, at least in the early stages, promises hope where there was none.
Once mesothelioma River, lung cancer and breast cancer begin to spread – or metastisizing – there is little hope, despite this significant achievements in the field of cancer treatment, made over the past few decades.
About half of the cases of cancer of the colon and rectum, as well as pancreatic cancer is diagnosed too late to respond to standard treatments, such as chemotherapy and radiation.
Immunotherapy began to change those odds, however.
These new treatments overload patient's own immune system to fight cancer.
Chief among the news of the last 20 years & # 39 is the development of so-called therapy CAR T cells.
CAR T therapy is carried out by taking a patient's own T cells – the type of immune cell – and Bioengineering them to attack cancer cells specifically.
Last year, Texas, immunologist, Dr. James Allison, was awarded the Nobel Prize for studies of T-cells, which paved the way for the CAR T therapy.
But the river, these procedures work to have been limited historically.
Immunotherapy prolong life and even cure people suffering from blood cancer, but not against solid tumors.
The new iteration of therapy, developed by scientists at Memorial Sloan Kettering in New York is on the verge of change.
Earlier CAR T cell is not against solid tumors, for two reasons.
Options & # 39; iruyuchy but significant proportion of breast, lung, ovary, pancreas, stomach, colorectal cancer, and mesothelioma marked protein called mesothelin, which acts as an armor on the surface of the tumor.
The car T-procedure showed such promise for the treatment of other cancers has not been a program aimed at these proteins.
Secondly, CART T therapy developed using the patient's own blood, and then, in the standard therapy, is poured back into the patient's blood.
But in the study of cancer and CARS T treatment in mice, a team of Memorial Sloan Kettering found that the cancer cells fighting came to light, persists for several days, and keep them from reaching and action on tumors.
So, Dr. Prasad Adusumilli and his staff were viewed as issues and provided new CAR T therapy some extra special features.
They again specially designed cells to seek and destroy the mesothelin protein to a solid surface to treat solid tumors.
Then, in cooperation with radiologists, the team has developed a way to make sure that the overloaded cells have reached their goal.
Instead of re-infusing therapeutic cells back into the patient's blood, they used the image-guided minimally invasive procedures for administration directly to a cell surface tumor.
And because the therapy is developed completely from the human genome, the patient's body does not reject the drug, and they do not have to take immunosuppressants – that the current CAR T patients should be throughout his life.
The treatment was thus able to "avoid the toxicity and efficiency by several times," said Dr. Adusimilli.
"This approach to & # 39 is the first in the world.
The study was only phase one clinical trial, so its long-term effects and safety are not yet clear. But if you continue to work, as well as he has, he can give about two million patients future terminal.